The addition of saxagliptin and dapagliflozin to metformin therapy increases treatment efficacy in patients with type 2 diabetes that is poorly controlled with metformin, according to a study published in Diabetes Care.
Lead researcher Julio Rosenstock, MD, of the Dallas Diabetes & Endocrine Center, and colleagues found that patients had more improvement with the addition of both saxagliptin and dapagliflozin to metformin compared with only the addition of either saxagliptin or dapagliflozin.
The double blind trial included adults with HbA1c ≥8.0% and ≤12.0% who were randomly assigned to saxagliptin plus dapagliflozin, saxagliptin plus placebo or dapagliflozin plus placebo to supplement their metformin treatment. The researchers measured changes from baseline HbA1c in all participants.
Mean baseline HbA1c was 8.9%. At 24 weeks, the adjusted mean change from baseline was –1.5% for all three drugs, –0.9% for saxagliptin plus metformin and –1.2% for dapagliflozin plus metformin.
The proportion of patients achieving HbA1c <7% was 41% for patients using all three drugs, 18% for those using saxagliptin plus metformin and 22% for those using dapagliflozin plus metformin.
Hypoglycemia was reported infrequently, with no reports of major hypoglycemia.
The study results indicate that adding both saxagliptin and dapagliflozin to metformin treatment is more effective in improving glycemic control in patients with diabetes than the addition of either saxagliptin or dapagliflozin alone.
OBJECTIVE: This study compared the efficacy and safety of dual add-on of saxagliptin plus dapagliflozin versus saxagliptin and dapagliflozin added on alone in patients with type 2 diabetes poorly controlled with metformin.